Choreo LLC Raises Holdings in Kenvue Inc. (NYSE:KVUE)

Choreo LLC raised its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 36.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,792 shares of the company's stock after purchasing an additional 13,506 shares during the period. Choreo LLC's holdings in Kenvue were worth $1,077,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Grove Bank & Trust grew its stake in shares of Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after acquiring an additional 947 shares during the last quarter. Riverview Trust Co purchased a new stake in shares of Kenvue during the third quarter worth about $30,000. Geneos Wealth Management Inc. purchased a new stake in shares of Kenvue during the fourth quarter worth about $29,000. Ashton Thomas Securities LLC purchased a new stake in shares of Kenvue during the third quarter worth about $35,000. Finally, Fortitude Family Office LLC boosted its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Kenvue Price Performance

Shares of KVUE stock traded up $0.05 during trading hours on Wednesday, hitting $20.96. 10,316,961 shares of the company's stock were exchanged, compared to its average volume of 12,673,827. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $40.19 billion, a P/E ratio of 39.55, a P/E/G ratio of 2.16 and a beta of 1.45. The firm has a 50 day moving average of $21.41 and a two-hundred day moving average of $22.03. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last announced its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Sell-side analysts forecast that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of recent research reports. Bank of America upped their target price on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. Barclays dropped their target price on Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research report on Friday, January 17th. Canaccord Genuity Group dropped their target price on Kenvue from $27.00 to $24.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. Finally, Piper Sandler upgraded Kenvue from a "neutral" rating to an "overweight" rating and upped their target price for the company from $21.00 to $26.00 in a research report on Monday, January 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.